Medical News

RSS

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

13 Sep 2010

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.

13 Sep 2010

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Anacor Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Anacor.

13 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Men with low PSA level does not benefit further treatment: Study

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.

13 Sep 2010

Bioscience companies to present novel technologies at BioFlorida's conference

A group of a dozen bioscience companies chosen through a competitive process will present their novel technologies to investors, business development executives, scientists and product or service providers at BioFlorida's 13th Annual Conference, scheduled for October 24 - 26 at the Marriott Harbor Beach in Ft. Lauderdale.

13 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

Scientists discover SNP association with primary open-angle glaucoma risk

Scientists at deCODE genetics and academic colleagues from Iceland, China, Sweden, the UK and Australia today report the discovery of the most important single-letter variation (SNP) in the sequence of the human genome yet associated with risk of primary open-angle glaucoma. This is the most common form of glaucoma and a major cause of blindness worldwide.

13 Sep 2010

CRT agrees with AstraZeneca for AZD-3965 clinical trial

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm have reached an agreement with AstraZeneca to take compound AZD-3965 a first-of-its-kind experimental drug to potentially treat a range of cancers into clinical trial.

13 Sep 2010

Catch by Gene enters agreement with C&S for HPV test kit

Catch by Gene has entered into an agreement to supply its reagent solutions to C&S Company Ltd commencing immediately in the initial amount of $300,000.

13 Sep 2010

Current economic crisis threatens to affect cancer incidence: Report

Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue of the European Journal of Cancer on cancer prevention, published today.

13 Sep 2010

Republicans shifting campaign focus beyond health care

Republicans had promised to make the fall elections a reprise of the bitter, exhausting debate over what they call 'Obamacare',The Boston Globe reports. But two months before the vote, the GOP has adopted a more nuanced approach and folded the issue into broader attacks on the Democrats' handling of the economy.

13 Sep 2010

Obama says increased health costs are factor of expanded coverage

President Obama on Friday defended the Democrats' healthcare law, saying the enormous expansion of insurance coverage made an increase in healthcare spending inevitable, The Hill reports.

13 Sep 2010

Measuring PSA levels effective in detecting prostate cancer: Study

A new multinational study suggests that regular blood testing to measure levels of prostate specific antigen (PSA) is more effective at detecting prostate cancer in men with a genetic predisposition to the disease.

13 Sep 2010

Researchers find amyloid precursor protein function in Alzheimer's disease

In people with Alzheimer's, the brain becomes riddled with clumps of protein, forming what are known as amyloid plaques. Now, a report appearing in the September 17th print issue of Cell appears to have found a function for the amyloid precursor protein that yields the prime ingredient in those plaques.

13 Sep 2010

Enlyton publishes cancer imaging study results of colorectal cancer

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.

13 Sep 2010

Improving palliative care may reduce healthcare costs, improve outcomes

There may be no simple one-size-fits-all approach to improving end-of-life care in ICU settings, according to a recent study from some of the world's leading researchers in palliative care.

13 Sep 2010

Covidien supports FDA labeling changes for gadolinium-based contrast agents

Covidien, a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, severe kidney disease.

13 Sep 2010

Unemployment federal programs fail to assist job seekers with disabilities: Study

Federal programs to assist the unemployed are failing job seekers with disabilities, according to an investigation by Jean Hall and Kathy Parker of the Center for Research on Learning at the University of Kansas.

13 Sep 2010

IRIN reports on efforts to better address moderate acute malnutrition

Aid groups in West Africa are trying out new strategies and products for treating moderate acute malnutrition (MAM) as part of a U.N.-led effort to change 30 year old policies, IRIN reports.

13 Sep 2010